• Cediranib (AZD2171) Workflows for Angiogenesis

  2026-09-21

  Learn how Cediranib (AZD2171) can separate VEGFR-driven angiogenic signaling from direct cancer-cell killing in vitro. This practical workflow combines endothelial assays, phospho-Akt measurements, and dual viability readouts to improve mechanism-focused cancer research.

• BRCA2 Protects RAD51 from PARP1 Retention

  2026-09-21

  The reference study identifies a previously unrecognized function of BRCA2: protecting RAD51 filaments from destabilization caused by PARP inhibitor-induced PARP1 retention on resected DNA. By combining biochemical reconstitution, single-molecule FRET, strand-exchange assays, and cellular localization microscopy, the work clarifies how BRCA2 status can influence responses to PARP inhibition and informs DNA repair deficiency targeting.

• Anlotinib and Multitarget Angiogenesis Inhibition

  2026-09-20

  The reference study shows that anlotinib suppresses angiogenesis by jointly inhibiting VEGFR2, PDGFRβ, and FGFR1 and their downstream ERK signaling. Its combination of endothelial-cell assays, ex vivo vessel sprouting models, and the chicken chorioallantoic membrane system provides a useful framework for evaluating multi-pathway anti-angiogenic compounds in cancer research.

• CF10–EdU Synergy Drives Telomere Attrition in CRC

  2026-09-19

  A 2026 NAR Molecular Medicine study shows that the fluoropyrimidine polymer CF10 strongly synergizes with EdU in colorectal cancer cells, whereas EdU plus 5FU is only additive. The combination increases EdU incorporation, DNA double-strand breaks, telomere signal loss, cell-cycle arrest, and mitotic catastrophe, defining a mechanism that links thymidylate stress to acute telomere dysfunction.

• RapaLink-1: A Third-Generation mTOR Workflow

  2026-09-18

  RapaLink-1 combines resistance-aware mTOR kinase inhibition with practical workflows for glioma assays, pathway validation, and exploratory dormancy studies. Its bivalent mechanism creates a useful bridge between cancer pharmacology and the reversible mTOR-dependent developmental states described in recent embryo and stem-cell protocols.

• Standardized Whole-Blood Stimulation in Immunometabolism

  2026-09-18

  The reference protocol establishes a standardized fresh whole-blood platform for measuring how metabolic interventions alter stimulus-induced immune responses. Its central contribution is to connect pattern-recognition or microbial stimulation with cytokine quantification and metabolism modulation in a physiologically complex, cohort-compatible assay.

• Patient-Derived Gastric Cancer Assembloids

  2026-09-17

  Shapira-Netanelov and colleagues developed a patient-derived gastric cancer assembloid system that combines matched tumor organoids with stromal subpopulations from the same tumor. The model reproduced clinically relevant tumor–stroma interactions and showed that stromal composition can reshape gene expression and drug sensitivity, supporting more realistic personalized drug testing.

• FLAG tag Peptide: From Proteostasis to Translation

  2026-09-17

  A mechanistic and strategic guide to using the FLAG tag Peptide (DYKDDDDK) for recombinant protein detection, purification, and translational studies informed by new insights into FtsH–HflK/C membrane proteostasis.

• Radicicol: Hsp90 Inhibitor Workflow Guide

  2026-09-16

  Radicicol is a versatile Hsp90 inhibitor and ATPase/kinase probe for dissecting antigen cross-presentation, adipocyte differentiation, apoptosis, and inflammatory signaling. This workflow guide connects mechanistic controls with practical assay design, dose selection, and troubleshooting across cell-based and sepsis inflammation model applications.

• Epacadostat in Whole-Blood IDO1 Assays

  2026-09-16

  Epacadostat (INCB024360) connects nanomolar IDO1 inhibition with standardized whole-blood immune-metabolism workflows. This guide shows how to measure target engagement, cytokine changes, and T-cell functional recovery while controlling solvent, timing, and matrix effects.

• PAD4-IN-2 TFA: Tumor-Targeted PAD4 Workflows

  2026-09-15

  PAD4-IN-2 TFA, also called Compound 5i TFA, combines PAD4 inhibition with meta-phenylboronic acid-mediated tumor targeting. This guide translates its reported effects on H3cit, NET formation, tumor-cell migration, and immune composition into practical workflows and troubleshooting decisions.

• Firefly Luciferase mRNA: ARCA and 5-moU Guide

  2026-09-15

  Firefly Luciferase mRNA (ARCA, 5-moUTP) is a capped, modified reporter transcript for translation, bioluminescence, gene expression assay, cell viability assay, and in vivo imaging workflows. Product specifications identify a 1,921-nucleotide transcript with an approximately 100-nucleotide poly(A) tail and storage at −40 °C or below.

• PDK4-IN-1 Hydrochloride: Assay-Ready PDH Studies

  2026-09-14

  PDK4-IN-1 hydrochloride is a selective pyruvate dehydrogenase kinase 4 inhibitor for connecting PDH activation with interpretable metabolic phenotypes. This guide develops an evidence-aware assay framework that separates biochemical potency, mitochondrial energy metabolism modulation, and disease-model relevance.

• Pexmetinib (ARRY-614) for Reliable Cell Assays

  2026-09-14

  This scenario-based guide explains how Pexmetinib (ARRY-614), SKU B6012, can help researchers distinguish cytokine-pathway modulation from nonspecific loss of cellular viability. It connects product-reported potency, formulation, storage, and assay findings with practical controls for inflammatory and myelodysplastic syndromes research.

• Dasatinib Monohydrate: Reliable Assay Design

  2026-09-13

  This scenario-driven guide explains how Dasatinib Monohydrate, SKU B5954, can support more interpretable kinase-inhibitor experiments in viability, proliferation, and cytotoxicity workflows. It connects product specifications with solvent control, dose-response design, and patient-derived assembloid data while defining practical limitations.

8414 records 1/561 page Next 12345 下5页 Last page